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Abstract
Testosterone concentrations in men are associated with cardiovascular morbidity, osteoporosis, and mortality and are affected by
age, smoking, and obesity. Because of serum testosterone’s high heritability, we performed a meta-analysis of genome-wide
association data in 8,938men from seven cohorts and followed up the genome-wide significant findings in one in silico (n=871) and
two de novo replication cohorts (n=4,620) to identify genetic loci significantly associated with serum testosterone concentration in
men. All these loci were also associated with low serum testosterone concentration defined as ,300 ng/dl. Two single-nucleotide
polymorphisms at the sex hormone-binding globulin (SHBG) locus (17p13-p12) were identified as independently associated with
serum testosterone concentration (rs12150660, p=1.2610241 and rs6258, p=2.3610222). Subjects with $3 risk alleles of these
variants had 6.5-fold higher risk of having low serum testosterone than subjects with no risk allele. The rs5934505 polymorphism near
FAM9B on the X chromosome was also associated with testosterone concentrations (p=5.6610216). The rs6258 polymorphism in
exon 4 of SHBG affected SHBG’s affinity for binding testosterone and the measured free testosterone fraction (p,0.01). Genetic
variants in the SHBG locus and on the X chromosome are associated with a substantial variation in testosterone concentrations and
increased risk of low testosterone. rs6258 is the first reported SHBG polymorphism, which affects testosterone binding to SHBG and
the free testosterone fraction and could therefore influence the calculation of free testosterone using law-of-mass-action equation.
PLoS Genetics | www.plosgenetics.org 1 October 2011 | Volume 7 | Issue 10 | e1002313
Citation: Ohlsson C, Wallaschofski H, Lunetta KL, Stolk L, Perry JRB, et al. (2011) Genetic Determinants of Serum Testosterone Concentrations in Men. PLoS
Genet 7(10): e1002313. doi:10.1371/journal.pgen.1002313
Editor: Gonc¸alo R. Abecasis, University of Michigan, United States of America
Received April 4, 2011; Accepted August 11, 2011; Published October 6, 2011
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: Framingham Heart Study (FHS): The FHS phenotype-genotype analyses for this work were supported by the National Institute of Aging (Genetics of
Reproductive Life Period and Health Outcomes, R21AG032598; JM Murabito, KL Lunetta, D Karasik, DP Kiel, WV Zhuang). The Framingham Heart Study of the National
Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine is supported by the National Heart, Lung, and Blood
Institute’s Framingham Heart Study Contract No. N01-HC-25195 and its contract with Affymetrix for genotyping services (Contract No. N02-HL-6-4278). Sex hormone
measurements were funded primarily by National Institute on Aging grant 1RO1AG31206 (PIs: S Bhasin and RS Vasan); additional support was provided by the Boston
Claude D. Pepper Older Americans Independence Center (5P30AG031679) and a grant from the National Institute on Aging and the National Institute of Arthritis
Musculoskeletal and Skin Diseases to DP Kiel (R01 AR/AG 41398). Analyses reflect intellectual input and resource development from the Framingham Heart Study
investigators participating in the SNP Health Association Resource (SHARe) project. A portion of this research was conducted using the Linux Cluster for Genetic
Analysis (LinGA-II), funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical
Center. Study of Health in Pomerania (SHIP): Computing resources have been made available by the Leibniz Supercomputing Centre of the Bavarian Academy of
Sciences and Humanities (HLRB project h1231). SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the
Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal
State of Mecklenburg – West Pomerania. Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint
grant from Siemens Healthcare, Erlangen, Germany, and the Federal State of Mecklenburg West Pomerania. The University of Greifswald is a member of the ‘‘Center of
Knowledge Interchange’’ program of the Siemens AG. This work is also part of the research project Greifswald Approach to Individualized Medicine (GANI_MED). The
GANI_MED consortium is funded by the Federal Ministry of Education and Research and the Ministry of Cultural Affairs of the Federal State of Mecklenburg – West
Pomerania (03IS2061A). The testosterone reagents used were sponsored by Siemens Healthcare Diagnostics, Eschborn, formerly DPC Biermann GmbH, Bad Nauheim,
Germany. Novo Nordisc provided partial grant support for the determination of serum samples and data analysis. Gothenburg Osteoporosis and Obesity Determinants
(GOOD) Study: Financial support was received from the Swedish Research Council (K2010-54X-09894-19-3, 2006-3832, and K2010-52X-20229-05-3), the Swedish
Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar So¨derberg’s Foundation, Petrus and
Augusta Hedlunds Foundation, the Va¨stra Go¨taland Foundation, the Go¨teborg Medical Society, the Novo Nordisk foundation, the Canadian Institutes of Health
Research (MOP-15261), and the European Commission grant HEALTH-F2-2008-201865-GEFOS. We would like to acknowledge Maria Nethander at the genomics core
facility at University of Gothenburg for statistical analyses. We would also like to thank Dr. Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as
their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and especially the national GermanMediGRID and Services@MediGRID part of the German
D-Grid, both funded by the German Bundesministerium fuer Forschung und Technology under grants #01 AK 803 A-H and# 01 IG 07015 G for access to their grid
resources. Cooperative Research in the Region of Augsburg (KORA): The KORA research platform was initiated and financed by the Helmholtz Center Munich, German
Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Part of this
work was financed by the German National Genome Research Network (NGFN-2 and NGFNPlus: 01GS0823). Our research was supported within the Munich Center of
Health Sciences (MC Health) as part of LMUinnovativ. This study was in part supported by a grant from the German Federal Ministry of Education and Research (BMBF)
to the German Center for Diabetes Research (DZD e.V.). Health, Aging, and Body Composition (Health ABC) Study: This study was supported by National Institute on
Aging contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake
Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal
contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. This research was supported (in part) by the
Intramural Research Program of the NIH, National Institute on Aging. Rotterdam study (RS1): The generation and management of GWAS genotype data for the
Rotterdam Study is supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012). This study is funded by the
Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI) – Netherlands Consortium of Healthy Aging (NCHA) project
nr. 050-060-810, and funding from the European Commision (HEALTH-F2-2008-201865, GEFOS; HEALTH-F2-2008-35627, TREAT-OA). The Rotterdam Study is funded by
Erasmus Medical Center and Erasmus University Rotterdam; Netherlands Organisation for Health Research and Development (ZonMw); the Research Institute for
Diseases in the Elderly (RIDE); the Ministry of Education, Culture, and Science; the Ministry for Health, Welfare, and Sports; the European Commission (DG XII); and the
Municipality of Rotterdam. We thank Pascal Arp, Mila Jhamai, Dr. Michael Moorhouse, Marijn Verkerk, and Sander Bervoets for their help in creating the GWAS
database. The authors are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practioners and pharmacists. We would
like to thank Dr. Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The
Netherlands, and especially the national German MediGRID and Services@MediGRID part of the German D-Grid, both funded by the German Bundesministerium fuer
Forschung und Technology under grants #01 AK 803 A-H and # 01 IG 07015 G for access to their grid resources. Invecchiare in Chianti (InCHIANTI): The InCHIANTI
study baseline (1998–2000) was supported as a ‘‘targeted project’’ (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the U.S. National Institute on Aging
(Contracts: 263 MD 9164 and 263 MD 821336); the InCHIANTI Follow-up 1 (2001–2003) was funded by the U.S. National Institute on Aging (Contracts: N.1-AG-1-1 and
N.1-AG-1-2111); the InCHIANTI Follow-ups 2 and 3 studies (2004–2010) were financed by the U.S. National Institute on Aging (Contract: N01-AG-5-0002); supported in
part by the Intramural research programof the National Institute on Aging, National Institutes of Health, Baltimore, Maryland. EuropeanMale Ageing Study (EMAS): The
EMAS is funded by the Commission of the European Communities Fifth Framework Programme ‘‘Quality of Life andManagement of Living Resources’’ Grant QLK6-CT-
2001-00258 and supported by funding from the UK Arthritis Research Campaign. The EMAS Principal Investigator is Professor Frederick Wu, MD; Dept of
Endocrinology, Manchester Royal Infirmary, UK. The ‘‘EMAS Study Group’’ consists of the following people: Gyorgy Bartfai, Steven Boonen, Felipe Casanueva, Joseph D
Finn, Gianni Forti, Aleksander Giwercman, Thang S Han, Kate L Holliday, Ilpo T Huhtaniemi, Krzysztof Kula, Michael EJ Lean, David M Lee, Terence W O’Neill, Neil
Pendleton, Margus Punab, Stephen R Pye, Alan J Silman, Abdelouahid Tajar, Wendy Thomson, Dirk Vanderschueren, and Frederick CW Wu. The authors wish to thank
the men who participated in the eight countries and the research/nursing staff in the eight centres: C Pott, Manchester, E Wouters, Leuven, M Nilsson, Malmo¨, M del
Mar Fernandez, Santiago de Compostela,M Jedrzejowska, Lodz, H-M Tabo, Tartu, A Heredi, Szeged for their data collection and C Moseley, Manchester for data entry
and project coordination. Dr. Vanderschueren is a senior clinical investigator supported by the Clinical Research Fund of the University Hospitals Leuven, Belgium. Dr.
Boonen is a senior clinical investigator of the Fund for Scientific Research-Flanders, Belgium (F.W.O.–Vlaanderen). Dr. Boonen is holder of the Leuven University Chair in
Metabolic Bone Diseases. The Osteoporotic Fractures in Men Study – Sweden (MrOS Sweden): Financial support was received from the Swedish Research Council
(K2010-54X-09894-19-3, 2006-3832), the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten
and Ragnar So¨derberg’s Foundation, Petrus and Augusta Hedlunds Foundation, the Va¨stra Go¨taland Foundation, the Go¨teborg Medical Society, the Novo Nordisk
Foundation, and the European Commission grant HEALTH-F2-2008-201865-GEFOS. The Cardiovascular Risk in Young Finns Study (YFS): YFS has been financially
supported by the Academy of Finland (grant no. 117797, 121584, and 126925), the Social Insurance Institution of Finland, Turku University Foundation, Tampere and
Turku University Hospital Medical Funds, Emil Aaltonen Foundation (T.L), Juho Vainio Foundation, Paavo Nurmi Foundation, the Tampere Tubeculosis Foundation, the
Orion-Farmos Research Foundation, Finnish Foundation of Cardiovascular Research, and Finnish Cultural Foundation. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: claes.ohlsson@medic.gu.se
. These authors contributed equally to this work.
" These authors were joint senior authors on this work.
GWAS of Testosterone
PLoS Genetics | www.plosgenetics.org 2 October 2011 | Volume 7 | Issue 10 | e1002313
Introduction
Testosterone, the most important testicular androgen in men, is
largely bound to two plasma proteins. Most of the circulating
testosterone (,50–60%) is bound with high affinity to sex
hormone-binding globulin (SHBG), while a smaller fraction (40–
50%) is bound loosely to albumin, and 1–3% is unbound and
termed free testosterone [1]. In prospective cohort studies, low
serum testosterone concentrations are associated with cardiovas-
cular morbidity, metabolic syndrome [2,3], dyslipidemia [4],
hypertension [5], type 2 diabetes mellitus [6], stroke [7],
atherosclerosis [8–10], osteoporosis, sarcopenia, and increased
mortality risk [11–13]. Thus, there is growing evidence that serum
testosterone is a valuable biomarker of men’s overall health status.
Since age, body mass index (BMI), and smoking are known to
affect serum testosterone concentrations [14], we used these
parameters as common set of covariates in all association models.
Studies in male twins indicate that there is a strong heritability of
serum testosterone, with genetic factors accounting for 65% of the
variation in serum testosterone [15]. However, the genetic
determinants of serum testosterone and the genetic risk factors
for low concentrations are poorly understood. Given the current
gap in knowledge of the genetic factors that contribute to the inter-
individual variability in serum testosterone concentration in men
we conducted a meta-analysis of genome-wide association studies
(GWAS). This two-stage meta-analysis included data from 14,429
Caucasian men from 10 independent cohorts within the Cohorts
for Heart and Aging Research in Genomic Epidemiology
(CHARGE) consortium. In stage one, the discovery stage,
genome-wide association data from seven cohorts were meta-
analyzed (n= 8,938) and all genome-wide significant findings that
fulfilled the criteria described in the methods section were followed
up in the three replication cohorts: one in silico replication cohort
(n = 871) and two replication cohorts with de novo genotyping
(n = 4,620). All association analyses of the discovery stage were
conducted both with and without additional adjustment for serum
SHBG concentrations. Our primary aim was to identify genetic
variants reproducibly associated with serum testosterone concen-
trations in men, evaluated as a continuous trait. We also assessed
whether the lead single-nucleotide polymorphisms (SNPs) from the
continuous trait analyses had a significant influence on the risk of
having low serum testosterone, defined as ,300 ng/dl [16]. This
level is slightly lower than that suggested recently by Wu et al.
[11 nmol/l = 317 ng/dl] as one of the clinical criteria for late
onset hypogonadism [17].
Results
Meta-analyses of genome-wide association studies for
autosomal SNPs
We performed a GWAS of serum testosterone concentrations,
investigating ,2.5 million SNPs in 8,938 men of Caucasian
ancestry, 18 to 98 years, from seven cohorts. Genome-wide
significant SNPs were found in the discovery analysis at one locus
on chromosome 17 (17p13-p12) using the criteria described in the
methods. The strongest association was found for rs12150660
(p = 1.9610217), located 11.5 kb upstream of the major transcrip-
tion start site of sex hormone-binding globulin (SHBG), with a minor
allele frequency (MAF) of 23% (Table 1 [SNPs rs12150660 and
rs6258], Figure 1A and Figures S1A, S2 and S3). Tests for
independently associated SNPs with serum testosterone in this
region revealed a second SNP, rs6258 (p = 4.1610214), which
represents a missense (PRL) polymorphism located in exon 4 of
SHBG (Table 1 [SNPs rs12150660 and rs6258], Figure 1B) and
which had a MAF of 2%. Based on HapMap release 22 (CEU),
the r2 between rs12150660 and rs6258 was 0.004. To validate the
independence of these two SNPs, conditional meta-analysis of the
discovery cohorts including both rs12150660 and rs6258 in an
additive genetic linear model adjusted for covariates was calcu-
lated. Because the associations remained significant and mostly
unchanged (rs12150660, p= 7.0610214; rs6258, p= 1.6610213),
both SNPs were independently associated with serum testosterone
concentrations. No additional autosomal locus fulfilled the criteria
for genome-wide significance.
Replication of autosomal hits
The associations of rs12150660 and rs6258 were confirmed
in the three replication cohorts (in silico replication in YFS and
de novo replication in MrOS Sweden and EMAS), demonstrat-
ing a combined p-value in the discovery and the replication
cohorts of 1.2610241 and 2.3610222, respectively (Table 1 [SNPs
rs12150660 and rs6258]). Both SNPs showed considerable
heterogeneity of results across the studies as measured by the I2
statistic [18]. The I2 values for the discovery meta-analysis using
the untransformed total testosterone values were 76.7% and
81.6% for rs12150660 and rs6258, respectively. The heterogeneity
was reduced to 39.3% and 75.5% for rs12150660 and rs6258,
respectively, by meta-analysing the z-score based untransformed
total testosterone values and to 30.9% and 78.0%, respectively, by
meta-analysing the inverse-normal transformed testosterone val-
ues. For rs12150660, a substantial amount of heterogeneity could
be explained by phenotypic variation among the cohorts, whereas
for rs6258 one cohort (InCHIANTI) showed consistent opposite
effect directions in all models used. To take into account this
heterogeneity, we additionally calculated a random effects model
for untransformed total testosterone values. The association for
rs12150660 remained genome-wide significant in the combined
discovery and replication stage meta-analysis, the association for
Author Summary
Testosterone is the most important testicular androgen in
men. Low serum testosterone concentrations are associ-
ated with cardiovascular morbidity, metabolic syndrome,
type 2 diabetes mellitus, atherosclerosis, osteoporosis,
sarcopenia, and increased mortality risk. Thus, there is
growing evidence that serum testosterone is a valuable
biomarker of men’s overall health status. Studies in male
twins indicate that there is a strong heritability of serum
testosterone. Here we perform a large-scale genome-wide
association study to examine the effects of common
genetic variants on serum testosterone concentrations. By
examining 14,429 men, we show that genetic variants in
the sex hormone-binding globulin (SHBG) locus and on the
X chromosome are associated with a substantial variation
in serum testosterone concentrations and increased risk of
low testosterone. The reported associations may now be
used in order to better understand the functional
background of recently identified disease associations
related to low testosterone. Importantly, we identified the
first known genetic variant, which affects SHBG’s affinity
for binding testosterone and the free testosterone fraction
and could therefore influence the calculation of free
testosterone. This finding suggests that individual-
based SHBG-testosterone affinity constants are required
depending on the genotype of this single-nucleotide
polymorphism.
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rs6258 reached genome-wide significance after excluding the
InCHIANTI cohort (Table S3).
The genetic influence on low serum testosterone
concentrations
In Table 2, the serum testosterone concentrations according to
genotype are given for the three replication cohorts. As expected,
mean serum testosterone concentrations were found to be lower in
men with GG than in those with TT genotype for rs12150660.
Similarly, men with the CT genotype for rs6258 had lower serum
testosterone concentrations than those with CC genotype. The TT
genotype of rs6258 was extremely rare and only found in two
subjects in the replication cohorts. The two autosomal SNPs
identified by GWAS had a significant influence on the risk of
having low serum testosterone (serum testosterone ,300 ng/dl) in
both the discovery and the replication cohorts with a combined
odds ratio (OR) per minor allele of 0.72 (95% CI, 0.65 – 0.79) and
2.7 (95% CI, 2.1 – 3.5) for rs12150660 and rs6258, respectively
(Figure 2A). We analyzed the combined effect of the two SNPs on
the risk of having low serum testosterone concentrations according
to the number of combined risk alleles for rs12150660 (G) and
rs6258 (T) in the three replication cohorts (MrOS Sweden, EMAS,
and YFS). The risk of having low serum testosterone concentra-
tions increased by the number of risk alleles with an OR of 1.62
(95% CI, 1.41 – 1.86) for each risk allele (Figure S4). Low serum
testosterone concentrations were 6.5-times more prevalent in men
with $3 risk alleles (30.1% prevalence of low serum testosterone)
compared to men without any risk allele (4.6% prevalence of low
serum testosterone; Figure 2B).
The role of SHBG in the observed associations
As SNP rs12150660 is located 11.5 kb upstream of SHBG and
SNP rs6258 is non-synonymous and located in exon 4 of SHBG,
we evaluated the influence of these polymorphisms on SHBG
concentrations. Both of these polymorphisms demonstrated a
significant association with SHBG concentrations in both the
discovery and replication cohorts (Table 1 [SNPs rs12150660 and
rs6258]). However, even after adjusting for SHBG concentrations,
the associations between these two SNPs and serum testosterone
concentrations were still significant (p = 9.061028 for rs12150660
and p= 4.561027 for rs6258). Free testosterone calculated using
law-of-mass-action equation was not associated with either of the
two polymorphisms (Table 1 [SNPs rs12150660 and rs6258]). As
serum testosterone and SHBG are highly correlated (e.g., in
MrOS Sweden rs = 0.53), variations in SHBG concentration might
have influenced the observed associations of serum testosterone
with other non-SHBG-related loci. Therefore, we performed an
additional SHBG-adjusted genome-wide meta-analysis among the
discovery cohorts, wherein none of the non-SHBG-related
autosomal SNPs reached genome-wide significance (Figure S1B).
Table 1. Meta-analyses of discovery and replication cohorts.
SNPs rs12150660 and rs6258 (on chromosome 17 in SHBG) identified in GWAS for total testosterone
Discovery Replication Combined
A1/A2 FREQ* beta se p n beta se p n beta se p n
Testosterone (ng/dl)
rs12150660 T/G 0.23 26.4 3.1 1.9E-17 8938 38.8 3.6 2.3E-27 5429 31.8 2.3 1.2E-41 14367
rs6258 T/C 0.02 274.7 9.9 4.1E-14 8938 2102.9 16.3 2.9E-10 5483 282.3 8.5 2.3E-22 14421
SHBG (nmol/l)
rs12150660 T/G 0.23 3.6 0.3 3.0E-42 8366 4.4 0.4 8.5E-36 5682 3.9 0.2 2.1E-75 14048
rs6258 T/C 0.02 26.6 0.8 1.2E-15 8366 29.5 1.3 6.7E-14 5733 27.4 0.7 3.5E-27 14099
Testosterone (SHBG-adjusted)
rs12150660 T/G 0.23 11.1 3.0 2.5E-04 8366 11.6 3.0 9.9E-05 5414 11.3 2.1 9.0E-08 13780
rs6258 T/C 0.02 241.8 9.4 8.2E-06 8366 233.2 13.8 1.6E-02 5467 239.1 7.7 4.5E-07 13833
Calculated Free Testosterone (ng/dl)
rs12150660 T/G 0.23 20.1 0.1 9.6E-02 8366 0.1 0.1 1.6E-02 5414 0.0 0.0 3.9E-01 13780
rs6258 T/C 0.02 20.2 0.2 3.2E-01 8366 20.5 0.3 9.0E-02 5467 20.3 0.2 6.5E-02 13833
SNP rs5934505 (on chromosome X near FAM9B) identified in GWAS for SHBG-adjusted total testosterone
Discovery Replication Combined
A1/A2 FREQ* beta se p n beta se p n beta se p n
Testosterone (ng/dl) C/T 0.26 14.1 3.2 1.1E-05 5067 27.2 6.0 5.4E-06 3816 17.0 2.8 1.7E-09 8883
SHBG (nmol/l) C/T 0.26 20.2 0.3 5.9E-01 4607 0.5 0.7 4.7E-01 4072 20.1 0.3 8.5E-01 8679
Testosterone (SHBG-adjusted) C/T 0.26 18.1 3.1 8.5E-09 4599 27.7 4.7 4.4E-09 3801 21.0 2.6 5.6E-16 8400
Calculated Free Testosterone (ng/dl) C/T 0.26 0.4 0.1 4.0E-07 4607 0.6 0.1 8.7E-10 3801 0.5 0.1 6.7E-15 8408
Effects size is given per minor allele. All seven discovery cohorts (n = 8,938) were included in the GWAS of chromosomes 1–22 while only the two largest cohorts (FHS
and SHIP. n = 5,067) had GWAS data available for the X chromosome. A1 = allele 1. A2 = allele 2. FREQ* = Frequency of allele 1. In the KORA cohort, testosterone was
measured using plasma but the analyses after excluding KORA yielded similar results. Calculated free testosterone was calculated for all subjects with both testosterone
and SHBG available by using a modified law of mass action equation. The concentrations of testosterone and SHBG and a fixed value for SHBG’s dissociation constant
were used in these calculations.
doi:10.1371/journal.pgen.1002313.t001
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The rs6258 polymorphism affects SHBG binding affinity
for testosterone and the measured free testosterone
fraction
As rs6258 is non-synonymous (P156L) and located in exon 4 of
SHBG, we evaluated the serum SHBG steroid-binding capacity of
the different rs6258 genotypes. As shown in Figure S5, serum
SHBG from CT but not CC subjects had a lower steroid-binding
capacity than expected from values obtained by an SHBG
immunoassay (p = 0.003). Therefore, we analyzed the SHBG
affinity for testosterone using Scatchard plots of SHBG in serum of
men with the rs6258 genotype (Figure 3A), and revealed
(Figure 3B) a higher mean dissociation constant (Kd) indicative
of a lower affinity in CT (Kd= 4.5 nM) and TT (Kd= 4.9 nM)
individuals than in CC individuals (Kd= 2.8 nM). Recombinant
SHBG corresponding to the T genotype demonstrated a higher
dissociation constant (lower affinity) compared with recombinant
SHBG corresponding to the C genotype (T genotype Kd 2.5 nM;
C genotype Kd 1.2 nM, Figure 3C). In addition, the free
testosterone fraction measured by an equilibrium dialysis method
was 22% higher (p = 1.461025) in serum from CT subjects than in
serum from CC subjects (Figure 3D).
X chromosome analyses
Imputed values for X chromosome-located SNPs were available
for the two larger discovery cohorts (SHIP and FHS; n= 5,067).
We performed meta-analyses of imputed X chromosome SNPs
for serum testosterone concentrations both with and without
SHBG adjustment, revealing one genome-wide significant associ-
ation for SNP rs5934505 (p= 8.561029) in the SHBG-adjusted
model (Table 1 [SNP rs5934505] and Figures S1B and S3). This
SNP was confirmed in the two replication cohorts with de novo
genotyping (MrOS Sweden p= 3.661023; EMAS p=1.561027).
Meta-analysis of discovery and replication cohorts resulted in a
combined p-value of 5.6610216. The rs5934505 SNP is located in
a CNV-insertion area (Xp22), 145 kb upstream of the family with
sequence similarity 9, member A (FAM9A) and 79 kb downstream of the
family with sequence similarity 9, member B (FAM9B) (Figure 1C). In
addition, rs5934505 is located 214 kb upstream of Kallmann
syndrome 1 sequence (KAL1). SNP rs5934505 was associated with
serum testosterone without SHBG-adjustment (combined p-value
of 1.761029) and with free testosterone (combined p-value of
6.7610215), but not with SHBG (Table 1 [SNP rs5934505]). The
mean serum testosterone and calculated free testosterone but not
SHBG concentrations were lower in men with T genotype than in
those with C genotype for rs5934505 (Table 2).
Discussion
This GWAS revealed novel genetic variants that significantly
affect circulating testosterone concentrations in men. The presence
of three or more risk alleles for the two polymorphisms in the
Figure 1. Regional association plots for single-nucleotide polymorphisms rs12150660, rs6258, and rs5934505. Regional association plot
of the two independent signals on chromosome 17 with either (A) rs12150660 or (B) rs6258 indicated by red diamond to evaluate linkage with other
single-nucleotide polymorphisms in the region. In addition, the association plot of the (C) rs5934505 signal on chromosome X is given. The r2 is based on
the CEU HapMap II samples. The blue line and right hand Y axis represent CEU HapMap II based recombination rates. (A) and (B) show the top SNPs of
the inverse-variance weighted discovery stage meta-analysis of untransformed serum testosterone and (C) show the top SNP of the SHBG-adjusted
serum testosterone using an imputation quality filter (observed/expected variance ratio) .0.4 at the individual cohort level during meta-analysis.
doi:10.1371/journal.pgen.1002313.g001
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SHBG loci resulted in markedly decreased testosterone concentra-
tions compared to men with two or less risk alleles. Importantly,
one of the identified genetic variations was associated with an
alteration in SHBG’s binding affinity for testosterone and the
measured free testosterone fraction. In addition, we identified a
locus on the X chromosome influencing serum testosterone
concentrations. The genetic contribution of the polymorphisms
to testosterone concentrations reported here is substantial; as a
reference for comparison, the effect of these polymorphisms on
testosterone concentrations in men is similar or greater than that
for known risk factors such as age, smoking, and BMI [19,20].
These findings improve our understanding of the genetic factors
that affect serum testosterone concentrations and contribute to the
variation in testosterone concentrations in men. These polymor-
phisms may assist in the identification of men at risk of low serum
testosterone, although the clinical usefulness of these findings
remains to be established. As rs12150660 and rs6258 were
strongly associated with SHBG concentrations, both SNPs may at
least partly affect total testosterone concentrations by modulating
SHBG concentrations. Our findings that rs6258 substantially
affects SHBG binding affinity and the measured free testosterone
fraction raise questions about the use of a single consensus value
for SHBG’s dissociation constant in the law of mass action
equations used to calculate free testosterone concentrations. As
emphasized by the Endocrine Society’s expert panel on androgen
deficiency syndromes, low testosterone concentrations alone
should not necessarily be viewed as evidence of androgen
deficiency [16]. Whether rs593405 near the FAM9B and KAL1
genes on Xp22 renders men susceptible to the increased risk of
androgen deficiency remains to be determined. Further studies are
required to determine the impact of these genetic variations on sex
steroid-related disorders, including osteoporosis, cardiovascular
diseases, prostate cancer, and male infertility [21].
Our studies add to the evidence that genetic variations within
the SHBG gene may explain some of the inter-individual
differences in SHBG concentrations. Our finding that SNP
rs6258 results in the production of an SHBG variant with reduced
affinity for testosterone provides an explanation for the association
between rs6258 and low serum testosterone concentrations. This is
the first described genetic variant associated with altered SHBG
binding for testosterone. As rs6258 is non-synonymous (P156L),
located in exon 4 of SHBG and associated with altered SHBG
binding for testosterone and free testosterone fraction, rs6258 is
likely a functional polymorphism with impact on testosterone
binding to SHBG as well as testosterone bioavailability and action
at target tissue level.
The SNP rs12150660 that is strongly associated with testoster-
one concentrations is located 11.5 kb upstream of the coding
sequence for SHBG mRNA production in the liver. However, it
still resides within the human SHBG locus because several other
alternative exon 1 sequences are located up to,13 kb upstream of
the exon 1 sequence that encodes the secretion signal polypeptide
of the SHBG precursor in the liver [22]. There are no obvious
nuclear protein binding sites within the sequences spanning SNP
rs12150660, and it remains to be determined whether this SNP
disrupts a cis-element that directly influences SHBG transcription.
We have found that rs12150660 is in strong LD (r2 = 0.89) with
another common SNP (rs1799941) in the SHBG proximal
promoter that was shown to be associated with serum SHBG
concentrations [23–25]. Thus, it is highly likely that only one of
these polymorphisms is actually functional and therefore both
SNPs represent the same signal. It should also be noted that
rs1799941 is linked to the number of TAAAA repeats within an
Alu sequence upstream of SHBG promoter [26] and that the
rs1799941 (A allele) is linked with the presence of six TAAAA
repeats in this location which has been reported to be associated
with higher SHBG concentrations [27]. In addition, while there
does not appear to be any putative transcriptional factor binding
sites with the sequence comprising rs12150660, it remains to be
determined whether rs12150660 or these other associated SNPs in
Table 2. Serum sex steroids in the three replication cohorts according to rs12150660, rs6258, and rs5934505 genotype.
SNPs identified in GWAS for total testosterone
SNP identified in GWAS for
SHBG-adjusted testosterone
rs12150660 rs6258 rs5934505
GG GT TT p-value CC CT TT p-value C T p-value
EMAS (n = 1310) (n = 833) (n = 152) (n = 2261) (n = 34) (n = 410) (n = 1120)
Testosterone (ng/dl) 4546161 4906172 5446181 ,0.001 4746169 3586104 ,0.001 4956178 4736168 0.02
Calculated Free
Testosterone (ng/dl)
8.4762.53 8.5362.53 8.8462.85 0.15 8.5262.56 8.1462.14 0.39 9.0062.65 8.4562.49 ,0.001
SHBG (nM) 39.6617.1 45.2620.4 51.6620.8 ,0.001 42.6619.0 26.8610.6 ,0.001 42.4620.5 42.8618.9 0.69
MrOS Sweden (n = 1317) (n = 844) (n = 123) (n = 2245) (n = 31) (n = 530) (n = 1765)
Testosterone (ng/dl) 4356170 4756177 5266171 ,0.001 4566174 3316125 ,0.001 4736177 4486173 0.005
Calculated Free
Testosterone (ng/dl)
7.9863.07 8.3063.16 8.7562.99 0.005 8.1663.08 7.5962.72 0.31 8.5463.27 8.0363.03 0.001
SHBG (nM) 41.0621.6 45.8622.4 49.8623.0 ,0.001 43.5622.0 24.3612.3 ,0.001 43.7624.1 43.1621.5 0.51
YFS (n = 522) (n = 329) (n = 51) (n = 852) (n = 48) (n = 2)
Testosterone (ng/dl) 5256182 5496246 5616158 0.063 5406209 4716157 441675 0.065 NA
Calculated Free
Testosterone (ng/dl)
11.8965.30 12.3068.92 11.5762.46 0.71 12.0466.90 11.8063.42 11.5561.23 0.80 NA
SHBG (nM) 30.0611.7 31.3611.9 35.2613.1 0.007 31.2612.0 23.068.1 20.564.0 ,0.001 NA
NA=not available. Free testosterone was calculated for all subjects with both testosterone and SHBG available by using a modified law of mass action equation. The
concentrations of testosterone and SHBG and a fixed value for SHBG’s dissociation constant were used in these calculations.
doi:10.1371/journal.pgen.1002313.t002
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the SHBG gene are functionally important or simply represent
proxies of SHBG and testosterone concentrations in men.
Our meta-analyses of imputed X chromosome SNPs revealed
one genome-wide significant association for SNP rs5934505,
located in a CNV-insertion area (Xp22), 145 kb upstream of family
with sequence similarity 9, member A (FAM9A) and 79 kb downstream
of family with sequence similarity 9, member B (FAM9B). Both genes,
FAM9A and FAM9B, are expressed exclusively in the testis [28]
and described here for the first time to be associated with total as
well as free testosterone concentrations. rs5934505 is located
214 kb upstream of Kallmann syndrome 1 sequence (KAL1).
Although the Kallmann syndrome, a type of hypogonadotropic
hypogonadism associated with anosmia and other congenital
anomalies, has been linked to mutations in the KAL1 gene on the
X chromosome, only 11–14% of Caucasian patients with
hypogonadotropic hypogonadism have detectable KAL1 mutations
[29], reflecting the considerable genetic heterogeneity of this
syndrome.
Figure 2. The genetic influence on low serum testosterone concentrations. (A) Odds ratio (OR) for risk of low serum testosterone
concentrations (serum testosterone ,300 ng/dl), per copy of minor allele. Summary estimates of the OR and their 95% confidence intervals (CI) are
given. The size of the data markers is proportional to the weight (inverse of the variance) of each study. Combined discovery (n = 8,030, low serum
testosterone 13%; KORA was not included as testosterone was analyzed in plasma rather than in serum, combined replication (n = 5,504, low serum
testosterone 13%), and combined discovery and replication (n = 13,534, low serum testosterone 13%). (B) Percentage of men with low serum
testosterone concentrations (serum testosterone ,300 ng/dl), according to the number of combined risk alleles for rs12150660 (G) and rs6258 (T) in
the three replication cohorts (MrOS Sweden, EMAS, and YFS). Only two individuals in the three replication cohorts had four risk alleles and therefore
individuals with three and four risk alleles were pooled into one group with $3 risk alleles.
doi:10.1371/journal.pgen.1002313.g002
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The strengths of our study include a discovery sample size of
8,938 men, which allowed us at the threshold a=561028,a 90%
power to detect SNPs accounting for 0.5% of the total variance in
serum testosterone concentrations, and 99% power to detect SNPs
accounting for 1% of the total variance. The SNPs rs12150660,
rs6258, and rs5934505 explained 2.3%, 0.9%, and 0.6%,
respectively, of the variance in serum testosterone concentrations
when evaluated in the MrOS Sweden replication cohort. Future
meta-analyses including larger samples will probably reveal
additional loci associated with serum testosterone. Further
research into the functional significance of these variants will be
needed to enable the translation of these findings into the
mechanisms of sex steroid-related diseases and strategies for risk
assessment. As the causal or etiological role of these polymor-
phisms in the genesis of low testosterone has not been established,
the reported polymorphisms associated with low serum testoster-
one concentration may be viewed currently as risk markers rather
than causal risk factors.
In conclusion, genetic variants in the SHBG locus and on the X
chromosome are associated with a substantial variation in
testosterone concentrations and increased risk of low testosterone
in men. Further studies are needed to determine the impact of
these genetic variations on sex hormone-related disorders. rs6258
is the first reported SHBG polymorphism, which affects testoster-
one binding to SHBG and the free testosterone fraction and could
therefore influence the calculation of free testosterone using law-
of-mass-action equation.
Methods
Study samples and genotyping
The discovery stage of the GWAS included 8,938 Caucasian
men of European descent drawn from seven epidemiological
cohorts: the Framingham Heart Study (FHS), the Study of Health
in Pomerania (SHIP), the Gothenburg Osteoporosis and Obesity
Determinants (GOOD) study, the Cooperative Health Research in
Figure 3. SHBG affinity for testosterone. (A and B) Scatchard plots of SHBG binding affinity for testosterone in serum samples according to
rs6258 genotype. (A) Representative Scatchard plots of serum SHBG binding to [3H]testosterone. Serum from individuals homozygous for the wild-
type SHBG allele (CC dashed line) or the rs6258 SNP (TT, solid line), or heterozygous for these alleles (CT, solid line). (B) Dissociation constant (Kd) of
serum SHBG according to rs6258 genotype (CC, n = 4 subjects; CT, n = 4 subjects; TT [rare variant] n = 1 and the variation for the TT subject is derived
from three separate analyses). (*) p = 0.001. Values are means 6 SEM. (C) Representative Scatchard plots of recombinant SHBG binding to
[3H]testosterone. Recombinant wild type ( =WT, C genotype; dashed line) or rs6258 (T genotype; solid line) SHBG expressed by CHO cells was diluted
1:10 and subjected to Scatchard analysis, as in panel A. (D) Free testosterone fraction in serum measured by an equilibrium dialysis method according
to rs6258 genotype (CC, n = 87 subjects; CT, n = 32 subjects). Values are means 6 SEM.
doi:10.1371/journal.pgen.1002313.g003
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the Region of Augsburg (KORA) study, the Health, Aging and
Body Composition (HEALTH ABC) study, the Rotterdam Study
(RS1), and the Invecchiare in Chianti (InCHIANTI) (Table S1).
The replication stage consisted of 4,620 men from two
epidemiological cohorts (the European Male Ageing Study
[EMAS] and the Osteoporotic Fractures in Men [MrOS] Sweden
study) for de novo genotyping of the top SNPs and one additional
cohort (the Young Finns Study, [YFS, n= 871]) with genome-wide
association data available and joining the study after stage one was
finished for in silico replication (Table S2).
Exclusion criteria included chemical or surgical castration and/
or medications affecting sex hormones such as steroid 5-alpha
reductase inhibitors, and sex hormone antagonists. All studies were
approved by local ethics committees and all participants provided
written informed consent. Characteristics of the study samples and
detailed descriptions of the participating cohorts, genotyping
methods, quality control, and imputation procedures are provided
in Text S1.
Genotyping and statistical analyses
Altogether, ,2.5 million SNPs, imputed using the HapMapII
CEU population, were tested for association with serum
testosterone in the discovery stage. Genome-wide association
analyses using an additive genetic linear regression model adjusted
for age, BMI, and current smoking were conducted twice within
each of the discovery cohorts using serum testosterone expressed
as ng/dl, as well as inverse-normal transformed serum testosterone
as outcomes.
To examine the robustness of the discovery results and to
reduce the risk of spurious associations due to possible testosterone
measurement heterogeneity between the individual cohorts, three
different types of meta-analyses were performed in the discovery
stage: 1) an inverse-variance weighted fixed effect model; 2) a z-
score based analysis of the untransformed serum testosterone
concentrations; and 3) a z-score based meta-analysis of the inverse-
normal transformed values. Model 1) was used as main analysis
since it allowed the computation of effect estimates, whereas the
other two analysis models were used for verification and quality
control checks of the main findings. All meta-analyses were
performed using METAL (www.sph.umich.edu/csg/abecasis/
metal/). The random effects model of the two SHBG locus SNPs
was calculated using the R-package metafor (www.r-project.org).
Imputed genotypes were analyzed in all cohorts taking the
genotype uncertainties into account. Genomic control was applied
to each individual cohort’s results and to the discovery stage meta-
analysis to correct p-values for potential effects of mild population
stratification. The estimated genomic control lambda was low for
both the individual cohorts (range of lGC: 1.00–1.07) and the
meta-analyses (range of lGC: 1.01–1.02), suggesting little residual
confounding due to population stratification (Figure S2).
To reduce the variance on serum testosterone induced by
SHBG concentration, the GWAS included a genome-wide test for
association of untransformed serum testosterone concentrations
adjusted for age, BMI, current smoking, SHBG and SHBG2
concentrations, again using both an inverse-variance weighted
fixed effect as main analysis and a z-score based meta-analysis for
quality control purposes.
A threshold of p,561028 was established a priori as the level for
genome-wide significance in the discovery analyses [30]. SNPs that
reached genome-wide significance in the inverse-variance weight-
ed meta-analysis of untransformed serum testosterone concentra-
tions with or without adjustment for SHBG and which had
association results in at least five of the seven cohorts (for chr X:
two cohorts with data available) were selected for further analyses.
Notably, all autosomal SNPs that fulfilled these criteria also
reached genome-wide significance in the other two types of meta-
analyses. From these SNPs, all independent SNPs were taken to
the replication stage.
We also assessed whether the lead SNPs from the continuous
trait analyses were associated with low serum testosterone
concentration (defined as ,300 ng/dl [16]; this level is slightly
lower than that suggested recently by Wu et al [11 nmol/
l = 317 ng/dl] [17]) by binary logistic regression including the
same covariates in the model used for the main analysis and meta-
analyzing the within-cohort results using inverse-variance weight-
ed fixed-effect model. The KORA cohort was not included in the
meta-analyses of low serum testosterone as testosterone was
measured using plasma in this cohort.
We determined the number of low serum testosterone
concentration risk alleles (0 to 4) for the two lead SNPs of the
SHBG locus in each individual and assessed the risk of low serum
testosterone concentrations in the three replication cohorts (MrOS
Sweden, EMAS, and YFS) using a trend test. Since only two
subjects in the replication cohorts had four risk alleles, individuals
having three and four risk alleles were grouped into one category
to obtain more reliable effect estimates during the subsequent
analyses. Details of test for independence, SHBG related analysis
of the top SNPs and quality control steps performed can be found
in Text S1.
Sex hormone measurements
Methods for the measurement of serum testosterone and SHBG
are given in Text S1. Calculated free testosterone was for all
subjects with both testosterone and SHBG available (n = 13833;
Table 1 and Table 2) calculated by using a modified law of mass
action equation, as described by Mazer [31]. The concentrations
of testosterone and SHBG and a fixed value for SHBG’s
dissociation constant were used in these calculations.
Free testosterone fraction
Free testosterone fraction was measured by an equilibrium
dialysis method in 87 subjects with the CC genotype and 32
subjects with the CT genotype of rs6258 (Figure 3D) [32]. Detailed
description of the free testosterone fraction measurements is
provided in Text S1.
Sex hormone-binding globulin assays
In experiments evaluating SHBG binding capacity, serum
SHBG concentrations were determined by two-site immuno-
fluorometric assay (PerkinElmer Life Sciences, Turku, Finland)
[33], or by a steroid-binding capacity assay [34]. For steroid-
binding assays, serum samples were pre-incubated with dextran-
coated charcoal (DCC) to remove endogenous steroids, prior to
incubation with either [3H]5a-dihydrotestosterone ([3H]DHT;
specific activity 50 Ci/mmol) or [3H]testosterone (specific activity
40 Ci/mmol), bound from free [3H]steroid were separated using
DCC as the separation reagent [34]. The steroid-binding
properties of SHBG in diluted serum samples or tissue culture
medium were determined by Scatchard analysis [34]. For the
expression of SHBG protein, wild type (corresponding to the C
genotype of rs6258) and rs6258 (corresponding to the T genotype
of rs6258) SHBG cDNAs in the pRC/CMV expression vector
were transfected into CHO cells, and G418 was used for selection
of stably transfected cells. At near confluence, cells were washed
with PBS and cultured in serum-free SFM4CHO medium
(Thermo Scientific HyClone, Logan, UT) for four days before
the SHBG-containing medium was harvested.
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meta-analysis of untransformed serum testosterone (A) and SHBG-
adjusted serum testosterone (B) using an imputation quality filter
(observed/expected variance ratio) .0.4 at the individual cohort
level during meta-analysis. All seven discovery cohorts (n = 8,938)
were included in the GWAS of chromosomes 1–22 while only the
two largest cohorts (FHS and SHIP, n= 5,067) had GWAS data
available for the X chromosome.
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Figure S2 Quantile-quantile plot of the genome-wide associa-
tion results of the inverse-variance weighted meta-analysis of
untransformed serum testosterone including all SNPs (black) and
after removal of the SNPs of the SHBG locus (blue).
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Figure S3 Associations for (A) rs12150660 and (B) rs6258 with
testosterone and for (C) rs5934505 with SHBG-adjusted testoster-
one. Effects sizes are given per minor allele. Beta estimates and
their 95% confidence intervals are given. The size of the data
markers is proportional to the weight (inverse of the variance) of
each study.
(PDF)
Figure S4 Risk of low serum testosterone concentrations (serum
testosterone ,300 ng/dl), according to the number of combined
risk alleles for rs12150660 (G= risk allele) and rs6258 (T= risk
allele) in the three replication cohorts (MrOS Sweden, EMAS, and
YFS). Bars indicate 95% confidence intervals. Only two
individuals in the three replication cohorts had four risk alleles
and therefore individuals with three and four risk alleles were
pooled into one group with $3 risk alleles. Two risk allele counts
were used as reference, since this is the most prevalent amount
among the cohorts.
(PDF)
Figure S5 Subjects heterozygous for the SHBG allele containing
an rs6258 SNP have lower serum SHBG steroid-binding capacity
(Y-axis) when compared to the concentrations of SHBG measured
by immunoassay (X-axis). Serum SHBG concentrations from 10
individuals homozygous for the wild type SHBG allele (CC, dashed
regression line r2 = 0.872) or heterozygous for the rs6258 variant
SHBG allele (CT, solid regression line r2 = 0.866) were measured
by a time-resolved immunofluorometric assay[33], and a steroid-
binding capacity assay using [3H]DHT as the labelled ligand.[34]
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